<DOC>
	<DOCNO>NCT02089126</DOCNO>
	<brief_summary>The study objective demonstrate superiority safety combination therapy ( fix-dose combination ) Gemigliptin Glimepiride , compare Glimepiride monotherapy patient type 2 diabetes .</brief_summary>
	<brief_title>Phase III Trial Evaluate Efficacy Safety Gemigliptin 50mg qd Added Ongoing Glimepiride Fix-dose Combination Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . Patients type 2 diabetes 2 . Adults least 19 year old 3 . Patients take Glimepiride stable dose ( ≥4mg/day ) 8 week Visit 1 ( screen ) monotherapy Patients take Glimepiride stable dose ( ≥4mg/day ) Metformin 8 week Visit 1 ( screen ) combination therapy 4 . Patients satisfy follow HbA1c ( % ) criterion : 7 ≤ HbA1c ≤ 11 5 . Patients provided explanation objective , method , effect , etc . clinical trial whose informed consent form sign himself/herself his/her representative 6 . Patients fall one follow 3 case 1 . Patients surgically sterile 2 . Postmenopausal females 45 year age 2 year last menstruation 3 . Fertile premenopausal female patient male patient without surgical sterilization , agree use least two contraception method ( one barrier method must include ) 14 day administration last investigational product avoid pregnancy . 1 . Patients type 1 diabetes , diabetic ketoacidosis , diabetic coma precoma 2 . Patients gestational diabetes secondary diabetes 3 . Patients NYHA Class III , IV congestive heart failure arrhythmia require treatment 4 . Patients thyroid gland dysfunction TSH normal range 5 . Patients pituitary insufficiency adrenal insufficiency 6 . Patients hereditary problem , galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption 7 . Female patient pregnant breastfeed 8 . Patients whose BMI exceed 40 kg/m2 9 . Patients whose creatinine clearance 30mL/min/1.73m2 10 . Patients whose bilirubin level exceed 1.5 time upper limit normal range whose ALT/AST level exceed 2.5 time upper limit normal range 11 . Patients continuously take follow drug 2 week Visit 1 ( screen ) , need take continuously repeatedly cyclosporin , sirolimus , tacrolimus , nicotinic acid ( ≥1500mg/day ) , isotretinoin Strong CYP3A4 inducer : rifampicin ( rifampin ) , phenytoin , carbamazepine , rifabutin , phenobarbital warfarin , dicoumarin , digoxin systemic glucocorticoid 12 . Patients take antiobesity drug surgery relate obesity within 12 week Visit 1 ( screen ) 13 . Patients receive insulin GLP1 analogue treatment within 8 week prior Visit 1 ( screen ) 14 . Patients receive treatment due malignant tumor within 5years Visit 1 ( screen ) However , patient whose basal cell squamous cell skin cancer situ cervical cancer treat enrol . 15 . Patients history myocardial infarction , unstable angina coronary artery bypass surgery within 6 month prior Visit 1 ( screen ) 16 . Patients history alcohol drug addiction within 1 year prior Visit 1 ( screen ) 17 . Patients medical history hypersensitivity class Gemigliptin dipeptidyl peptidase 4 ( DPP 4 ) inhibitor drug 18 . Patients history hypersensitivity drug belong class Glimepiride sulfonylureas sulfonamide 19 . Patients participate another clinical trial within 3 month prior Visit 1 ( screen ) 20 . Patients deem unsuitable trial base judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>